Company profile: Prokarium
1.1 - Company Overview
Company description
- Provider of microbial immunotherapy and synthetic biology–based immuno-oncology therapeutics. Offers ZH9, an investigational intravesical monotherapy to prevent recurrences in non‑muscle invasive bladder cancer; the Living Cures Platform for delivering therapeutic cargo and nucleic acids; IO Prime, an oral immune fitness agent; and Entervax, a bivalent oral enteric fever vaccine in phase 1.
Products and services
- IO Prime: Develops an oral immune fitness agent that boosts the efficacy of immunotherapies for patients currently unable to benefit from existing treatments
- Living Cures Platform: Architects a synthetic-biology platform delivering diverse therapeutic cargo to difficult-to-treat cancers, producing therapeutic molecules within the tumor microenvironment and enabling targeted nucleic acid delivery
- ZH9: Engineers an investigational intravesical monotherapy for non-muscle invasive bladder cancer, focused on prevention of recurrences
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Prokarium
Mersana Therapeutics
HQ: United States
Website
- Description: Provider of biodegradable polymer and ADC platforms, including Fleximer; Dolasynthen to generate site-specific, homogeneous ADCs with proprietary payloads and target-optimized drug-to-antibody ratios; and Immunosynthen to create STING agonist ADCs that locally activate STING signaling. Pipeline includes XMT-1660 (B7-H4) and XMT-2056 targeting a novel HER2 epitope.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mersana Therapeutics company profile →
Alligator Bioscience
HQ: Sweden
Website
- Description: Provider of antibody-based immunotherapies for cancer, including next-generation CD40 agonists and bispecific CD40-targeting antibodies, developed using its FIND® (Fragment INduced Diversity) protein optimization technology, and discovering and developing drug candidates up to phase IIa clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alligator Bioscience company profile →
Cue Biopharma
HQ: United States
Website
- Description: Provider of biologic immunotherapies and a platform for cancer, chronic viral infections, and autoimmune diseases. Offerings include CUE-101 activating tumor-specific T cells against HPV16+ head and neck cancer; CUE-102/103 targeting additional tumor antigens and HLA alleles in solid tumors; CUE-200 activating virus-specific CD8+ T cells; CUE-300 inhibiting autoreactive CD4+ and enhancing regulatory T cells; CUE-301 for type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cue Biopharma company profile →
Nascent Biotech
HQ: United States
Website
- Description: Provider of therapeutic antibodies and platform technologies. Pritumumab is a natural human IgG antibody targeting ecto-domain vimentin on adenocarcinomas, including brain cancers and melanoma; MultiPharm is a multi-agent (antibodies and/or cytokines) platform for potential treatment of cancer, diabetes, autoimmunity, and transplantation; and CLNH5 is a patented technology with four patents awarded by the United States Patent Office.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nascent Biotech company profile →
SuppreMol
HQ: Germany
Website
- Description: Provider of biotechnology therapies pioneering a novel approach to treat autoimmune diseases, aiming to cure these disorders rather than merely manage symptoms; privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SuppreMol company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Prokarium
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Prokarium
2.2 - Growth funds investing in similar companies to Prokarium
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Prokarium
4.2 - Public trading comparable groups for Prokarium
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →